A pilot study of chemoimmunotherapy in the postconsolidation setting for high‐risk neuroblastoma (ANBL19P1): A report from the Children’s Oncology Group
Cancer · 2026
DOI: 10.1002/cncr.70165 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer, 2026. Verfasst von Ami V Desai und 13 weiteren Autor:innen. Beteiligte Einrichtung: Section of Hematology, Oncology, and Stem Cell Transplantation, Department of Pediatrics, University of Chicago, Chicago, Illinois, USA. Hauptthemen laut MEDLINE: Neuroblastoma, Antineoplastic Combined Chemotherapy Protocols, Immunotherapy. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: St. Baldrick's Foundation, National Clinical Trials Network Operations Center Grant, NCI NIH HHS.
Themen: Kinderkrankenpflege
Abstract (Originalsprache)
Background
Survival for patients with high‐risk neuroblastoma remains poor despite current‐era multimodality treatment that includes postconsolidation GD2‐directed immunotherapy. Given the promising responses in patients who receive dinutuximab‐based chemoimmunotherapy in the relapsed setting, the Children’s Oncology Group ANBL19P1 study evaluated the feasibility of administering irinotecan, temozolomide, dinutuximab, and sargramostim after frontline consolidation with tandem autologous stem cell transplantation (ASCT).
Methods
Patients with high‐risk neuroblastoma who received induction therapy followed by tandem ASCT and had no evidence of progressive disease (PD) were eligible. Treatment included five 28‐day cycles of temozolomide and irinotecan (days 1–5), dinutuximab (days 2–5), and sargramostim (days 6–12). Isotretinoin (days 8–21) was given during cycles 1–6. Therapy was deemed feasible if the 95% confidence interval placed on the percentage of patients that completed five cycles of chemoimmunotherapy without PD within 30 weeks contained 75% in the absence of excessive toxicity. Event‐free survival and overall survival were determined from the time of enrollment.
Results
Forty eligible patients enrolled, and 35 (87.5%; 95% confidence interval, 73.9%–94.5%) completed five cycles without PD within 30 weeks, meeting the feasibility threshold. No unacceptable toxicities occurred on protocol therapy, including no toxic deaths. Five patients discontinued therapy early because of physician determination ( n = 2), patient/parent refusal of further therapy ( n = 2), and PD ( n = 1). The 2‐year event‐free and overall survival rates were 82.5% ± 6.1% and 92.5% ± 4.2%, respectively.
Conclusions
The administration of chemoimmunotherapy in the postconsolidation setting after tandem ASCT is feasible and tolerable. Future studies will be needed to define the population most likely to benefit from this augmented postconsolidation therapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Section of Hematology, Oncology, and Stem Cell Transplantation, Department of Pediatrics, University of Chicago, Chicago, Illinois, USA.
- Children's Oncology Group Statistics and Data Center, University of Florida, Gainesville, Florida, USA.
- Aflac Cancer and Blood Disorders Center at Children's Healthcare of Atlanta and Emory University School of Medicine, Atlanta, Georgia, USA.
- St. Jude Children's Research Hospital, Memphis, Tennessee, USA.
- Children's Hospital of Philadelphia, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
- Lucile Packard Children's Hospital Stanford, Stanford, California, USA.
ORCID-Profile: Ami V Desai, Steven G DuBois
Förderung
- St. Baldrick's Foundation
- National Clinical Trials Network Operations Center Grant
- NCI NIH HHS
- National Clinical Trials Network Statistics and Data Center Grant
Zitieren
APA
Desai, A. V., Naranjo, A., LaBarre, B., Chen, L., Goldsmith, K. C., Granger, M. P., States, L., Green, S. G., Trunzo, M., Fitzgerald, W., DuBois, S. G., Bagatell, R., Park, J. R., & Marachelian, A. (2026). A pilot study of chemoimmunotherapy in the postconsolidation setting for high‐risk neuroblastoma (ANBL19P1): A report from the Children’s Oncology Group. Cancer. https://doi.org/10.1002/cncr.70165
Vancouver
Desai AV, Naranjo A, LaBarre B, Chen L, Goldsmith KC, Granger MP, et al. A pilot study of chemoimmunotherapy in the postconsolidation setting for high‐risk neuroblastoma (ANBL19P1): A report from the Children’s Oncology Group. Cancer. 2026. doi:10.1002/cncr.70165
BibTeX
@article{Desai2026,
author = {Desai, Ami V and Naranjo, Arlene and LaBarre, Brian and Chen, Lulu and Goldsmith, Kelly C and Granger, Meaghan P and States, Lisa and Green, Sean G and Trunzo, Mariel and Fitzgerald, Wendy and DuBois, Steven G and Bagatell, Rochelle and Park, Julie R and Marachelian, Araz},
title = {A pilot study of chemoimmunotherapy in the postconsolidation setting for high‐risk neuroblastoma (ANBL19P1): A report from the Children’s Oncology Group},
journal = {Cancer},
year = {2026},
doi = {10.1002/cncr.70165}
}
EUVIMED